文献速递胸部肿瘤放疗放疗物理与技术

胸部肿瘤再程放疗采用调强质子治疗

Reirradiation of thoracic cancers with intensity modulated proton therapy.
PubMed 文献 · Pract Radiat Oncol · 2017-07-08

回顾性分析27例胸部恶性肿瘤再程放疗患者接受调强质子治疗(IMPT),中位剂量66 EQD2 Gy。中位总生存18.0个月,1年局部控制率78%,仅2例(7%)出现晚期3级肺毒性,无4-5级毒性。

要点

  • IMPT再程放疗胸部肿瘤耐受性良好,无4-5级毒性,仅7%晚期3级肺毒性。
  • 中位随访11.2个月,中位总生存18.0个月,1年总生存率54%。
  • 剂量≥66 EQD2 Gy与更好的1年局部控制、区域控制和生存相关。

核心结论

  • IMPT用于胸部肿瘤根治性再程放疗可提供持久局部控制且毒性轻微。
  • 较高剂量可能改善结局,需进一步验证。

研究设计与样本

  • 2011-2016年回顾性分析27例接受IMPT再程放疗的胸部恶性肿瘤患者,均有既往胸部放疗史,剂量换算为EQD2。

主要发现

  • 中位随访11.2个月,中位总生存18.0个月,1年总生存率54%。
  • 4例(15%)发生野内局部失败,1年无局部失败率78%。
  • 1年无局部区域失败率和无进展生存率分别为61%和51%。
  • 仅2例(7%)出现晚期3级肺毒性,无3级及以上食管炎,无4-5级毒性。

关键数值与推荐

  • 患者接受IMPT中位剂量66 EQD2 Gy(范围43.2-84 Gy)。

临床怎么用

  • 对于既往接受过胸部放疗的复发或再程治疗患者,可考虑IMPT以安全给予较高剂量。
  • 剂量≥66 EQD2 Gy可能与更好的局部控制和生存相关。

局限性

  • 回顾性研究,样本量小(27例),随访时间较短(中位11.2个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Reirradiation of thoracic malignancies is a treatment challenge, with concerns for toxicity and the inability to deliver definitive doses. Intensity modulated proton therapy (IMPT) may allow safe delivery of a higher dose of radiation to the tumor while minimizing toxicities. METHODS AND MATERIALS: Between 2011 and 2016, 27 patients who received IMPT for reirradiation of thoracic malignancies with definitive intent were retrospectively analyzed. Patients were included if they received a prior thoracic radiation course. All doses were recalculated to an equivalent dose in 2-Gy fractions (EQD2). Patients received IMPT to a median dose of 66 EQD2 Gy (range, 43.2-84 Gy) for recurrence of thoracic cancer (93%) or sequentially after a course of thoracic stereotactic ablative radiation therapy (7%). RESULTS: Twenty-two patients (81%) were treated for non-small cell lung cancer. The median time to reirradiation was 29.5 months. At a median follow-up for all patients of 11.2 months (25.9 surviving patients), the median overall survival was 18.0 months, with a 1-year overall survival of 54%. Four patients (15%) experienced an in-field local failure (LF), with a 1-year freedom from LF rate of 78%. The 1-year freedom from locoregional failure and 1-year progression-free survival rates were 61% and 51%, respectively. Patients who received 66 EQD2 Gy or higher had improved 1-year freedom from LF (100% vs 49%; P = .013), 1-year freedom from locoregional failure (84% vs 23%; P = .035), and 1-year progression-free survival (76% vs 14%; P = .050). Reirradiation was well tolerated, with only 2 patients (7%) experiencing late grade 3 pulmonary toxicity, and none with grade 3 or higher esophagitis. There were no grade 4-5 toxicities. CONCLUSIONS: These data represent the largest series of patients treated with IMPT for definitive reirradiation of thoracic cancers. They demonstrate that IMPT provided durable local control with minimal toxicity and suggest that higher doses may improve outcomes.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ho JC, Nguyen QN, Li H, et al. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol. 2017. PMID: 28867546. doi:10.1016/j.prro.2017.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。